3篇
您的检索式：作者名="S.Nowakowski"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intrahepatic flow diversion prior to segmental Yttrium-90 radioembolization for challenging tumor vasculature显示文摘Background: Hepatic tumors with complex vascular supply or poor relative perfusion are prone to decreased rates of objective response. This is compounded in the setting of Yttrium-90(Y90) transarterial radioembolization(TARE), which is minimally embolic and flow-dependent, relying on high threshold dose for complete response.Objective: We describe our experience with intrahepatic flow diversion(FD) prior to TARE of hepatocellular carcinoma(HCC) with challenging vascular supply.Materials and methods: Between April 2014 and January 2020, 886 cases of coinciding MAA or TARE and bland embolization or temporary occlusion were identified.Intraprocedural embolizations performed for more routine purposes were excluded. FD was performed by bland embolization or temporary occlusion of vessels supplying non-malignant parenchyma in cases where flow was not preferential to target tumor. Lesion characteristics, vascular supply, treatment approach, angiography, and adverse events(AEs) were reviewed. Radiographic response was assessed using mRECIST criteria.Results: 22 cases of FD of focal HCC were identified. Embolics included calibrated microspheres(n = 11), microcoils(n = 4), gelfoam(n = 3), temporary balloon occlusion(n = 2) and temporary deployment of a microvascular plug(n = 1). Post-treatment SPECT-CT dosimetry coverage was concordant with target lesions in all cases. Mean follow-up was 16.7 months(1.4–45 mos). Tumor-specific response per m RECIST was 41% complete response, 50% objective response, and 59% disease control rate. No major adverse events or grade 3/4 hepatotoxicity were reported.Conclusion: Our findings suggest that FD prior to TARE is safe and potentially effective in treating HCC with complex vascular supply or poor tumor perfusion. | Lindsay B.Young Marcin Kolber Michael J.King Mona Ranade Vivian L.Bishay Rahul S.Patel Francis S.Nowakowski Aaron M.Fischman Robert A.Lookstein Edward Kim | 2022 | Journal of Interventional Medicine2022，5，2： | 1 |
| 2 | Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia显示文摘 | G. S.Nowakowski G. W.Dewald J. D.Hoyer S. F.Paternoster K. J.Stockero S. R.Fink S. A.Smoley E. D.Remstein R. L.Phyliky T. G.Call T. D.Shanafelt N. E.Kay C. S.Zent | 2005 | British Journal of Haematology2005，，1： | 1 |
| 3 | Diffuse large B-Cell lymphoma:from novel molecular classifications to tailored targeted therapies显示文摘Diffuse large B-cell lymphoma(DLBCL)is a heterogeneous disease comprising multiple genetic subtypes that translates and impacts clinical outcomes after standard chemoimmunotherapy.Our initial understanding of the complex biological subtypes of DLBCL began with the identification of cell of origin(COO),and now has evolved to include even more specific subtypes defined by genetic signatures and mutations.These newer classifications lend themselves to the application of precision-based medicine,allowing us to tailor new treatment platforms that target specific oncogenic drivers in order to improve DLBCL outcomes.Essential to this is the development of genetic assays and tools that are reliable and readily available to assist in the application of these molecular classifications to real-world use.In this review,we discuss the history of DLBCL classification systems and their implication on clinical investigation as well as novel therapeutic options in DLBCL. | Jennifer K.Lue Grzegorz S.Nowakowski | 2022 | Journal of Cancer Metastasis and Treatment2022，8，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员